Shots:

• The US FDA has issued a notification to Polpharma Biologics for the acceptance of BQ201’s (biosimilar- ranibizumab) BLA to treat wet AMD with an anticipated PDUFA date in Aug’22
• The launch of biosimilar ranibizumab may increase market competition- reduce cost & expand patient access with proven analytical & clinical similarity to Lucentis
• Coherus will exclusively commercialize BQ201 in the US- following the FDA's approval. Bioeq's proposed ranibizumab biosimilar BQ201 (formerly FYB201) has been originally licensed from Formycon AG

  | Ref: Businesswire | Image: Businesswire